Overview

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Active, not recruiting

Trial end date:
2026-12-08

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Collaborators:

Australia New Zealand Gynaecological Oncology Group
Gynecologic Oncology Group
Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology Group

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Veliparib